Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
OMED's Cash-to-Debt is ranked higher than
78% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. OMED: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OMED' s Cash-to-Debt Range Over the Past 10 Years
Min: 326.31  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset -0.24
OMED's Equity-to-Asset is ranked lower than
94% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OMED: -0.24 )
Ranked among companies with meaningful Equity-to-Asset only.
OMED' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.45  Med: 0.08 Max: 0.7
Current: -0.24
-2.45
0.7
Interest Coverage No Debt
OMED's Interest Coverage is ranked higher than
70% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OMED: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OMED' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -4.24
Beneish M-Score: -2.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -395.36
OMED's Operating Margin % is ranked lower than
67% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. OMED: -395.36 )
Ranked among companies with meaningful Operating Margin % only.
OMED' s Operating Margin % Range Over the Past 10 Years
Min: -411.03  Med: -127.97 Max: -48.52
Current: -395.36
-411.03
-48.52
Net Margin % -393.77
OMED's Net Margin % is ranked lower than
68% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. OMED: -393.77 )
Ranked among companies with meaningful Net Margin % only.
OMED' s Net Margin % Range Over the Past 10 Years
Min: -409.9  Med: -126.42 Max: -47.87
Current: -393.77
-409.9
-47.87
ROA % -50.91
OMED's ROA % is ranked lower than
66% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. OMED: -50.91 )
Ranked among companies with meaningful ROA % only.
OMED' s ROA % Range Over the Past 10 Years
Min: -50.91  Med: -25.92 Max: -12.61
Current: -50.91
-50.91
-12.61
ROC (Joel Greenblatt) % -2193.10
OMED's ROC (Joel Greenblatt) % is ranked lower than
64% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. OMED: -2193.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OMED' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2193.1  Med: -517.34 Max: -385.14
Current: -2193.1
-2193.1
-385.14
3-Year Revenue Growth Rate -35.00
OMED's 3-Year Revenue Growth Rate is ranked lower than
80% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. OMED: -35.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OMED' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -66.1 Max: -35
Current: -35
3-Year EBITDA Growth Rate 22.90
OMED's 3-Year EBITDA Growth Rate is ranked higher than
75% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. OMED: 22.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OMED' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -49.65 Max: 22.9
Current: 22.9
0
22.9
3-Year EPS without NRI Growth Rate 17.60
OMED's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. OMED: 17.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OMED' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50.5 Max: 17.6
Current: 17.6
0
17.6
GuruFocus has detected 2 Warning Signs with OncoMed Pharmaceuticals Inc $OMED.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OMED's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

OMED Guru Trades in Q2 2016

PRIMECAP Management 215,800 sh (unchged)
Paul Tudor Jones Sold Out
First Eagle Investment 77,370 sh (-58.05%)
» More
Q3 2016

OMED Guru Trades in Q3 2016

Jim Simons 251,600 sh (New)
PRIMECAP Management 1,302,700 sh (+503.66%)
First Eagle Investment 230,400 sh (+197.79%)
» More
Q4 2016

OMED Guru Trades in Q4 2016

Jim Simons 469,300 sh (+86.53%)
PRIMECAP Management 1,800,700 sh (+38.23%)
First Eagle Investment 230,400 sh (unchged)
» More
Q1 2017

OMED Guru Trades in Q1 2017

Jim Simons 533,600 sh (+13.70%)
PRIMECAP Management 1,906,600 sh (+5.88%)
First Eagle Investment 159,420 sh (-30.81%)
» More
» Details

Insider Trades

Latest Guru Trades with OMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CRME, NAS:PTGX, OTCPK:HSDT, NAS:FATE, OTCPK:AAVXF, NAS:QURE, NAS:DRNA, NAS:PSTI, NAS:BDSI, NAS:EVGN, NAS:SRNE, NAS:CBAY, NAS:SBPH, OTCPK:INNMF, NAS:REPH, OTCPK:VNLPY, NAS:VBLT, NAS:CDXC, NYSE:KDMN, AMEX:XXII » details
Traded in other countries:O0M.Germany,
Headquarter Location:USA
OncoMed Pharmaceuticals Inc is a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology product candidates.

OncoMed Pharmaceuticals Inc was originally incorporated in July 19, 2004 in Delaware. The Company is a clinical development-stage biopharmaceutical company focused on discovering and developing novel protein therapeutics targeting cancer stem cells, or CSCs. CSCs, also known as tumor-initiating cells, are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs exhibit certain properties which include the capacity to divide and give rise to new CSCs via self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor. Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. It faces competition from many pharmaceutical and biotechnology companies that are also researching and selling products designed to address these markets. The Company has a total of over 400 patents and pending patent applications in our patent portfolio. The Company's product candidates are subject to regulation by the FDA as biologics.

Top Ranked Articles about OncoMed Pharmaceuticals Inc

OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results
OncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial
OncoMed Pharmaceuticals to Report First Quarter Financial Results on May 8th, 2017
OncoMed Announces Workforce Reduction
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
OncoMed Pharmaceuticals Announces Bayer Terminates its Option to License Vantictumab or Ipafricept
OncoMed’s Phase 2 Demcizumab Pancreatic Cancer Trial Misses Primary Endpoint
OncoMed Highlights New Data Presented at the American Association for Cancer Research Annual Meeting 2017
OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017
OncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2017

Additional Presentations will Highlight New Biomarker and Xenograft Data for Clinical Programs

REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical immuno-oncology and anti-cancer stem cell therapeutic candidates in a total of six presentations at the upcoming American Association for Cancer Research (AACR) Meeting to be held April 1-5, 2017 in Washington, DC.
Among the presentations will be three posters detailing preclinical data for OncoMed’s novel anti-TIGIT (OMP-313M32) immuno-oncology therapeutic candidate.  These will be the first data that the company has shared publicly for its anti-TIGIT antibody program.  New data will also be presented on biomarker research associated with the Phase 1b portion of OncoMed’s tarextumab (anti-Notch2/3, OMP-59R5) clinical trial in small cell lung cancer and OncoMed’s preclinical GITRL-Fc trimer (OMP-336B11) program.  In addition, xenograft data will be presented for anti-RSPO3 (OMP-131R10) in combination with taxane chemotherapy in colorectal cancer. The following abstracts have been selected for presentation by OncoMed scientists: Sunday, April 2, 2017               1:00 PM – 5:00 PM
Title: Pharmacodynamic biomarkers for anti-TIGIT treatment and prevalence of TIGIT expression in multiple solid tumor types
Presenting author: Fiore Cattaruzza, Pharm. D., Ph.D., Senior Scientist II, Translational Medicine
Abstract Number: 599
Session: T-cell Immunity to Cancer: New Progress
Location: Poster section 26; Poster board 3 Monday, April 3, 2017               8:00 AM - Noon
Title: Antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains) induces anti-tumor immune response and generates long-term immune memory
Presenting author: Angie Inkyung Park, Ph.D., Senior Director Immunotherapy
Abstract Number: 2003
Session: Tumor Microenvironment
Location: Poster section 44; Poster board 18 Title: Circulating Tumor Cells (CTCs) in patients with extensive-stage small cell lung cancer and their association with clinical outcome  
Abstract number: 1727
Presenting author: Chun Zhang, Ph.D., Director, Translational Medicine
Session: Liquid Biopsies 1: Circulating Tumor Cells
Location: Poster section 30; Poster board 17 Title: R-SPONDIN3 antagonism sensitizes colorectal cancer to taxane treatment
Abstract Number: 1911
Presenting author: Marcus Fischer, Scientist
Session: Normal and Neoplastic Stem Cells
Location: Poster section 41; Poster board 12 Monday, April 3, 2017               1:00 PM – 5:00 PM
Title: Anti-TIGIT induces T cell mediated anti-tumor immune response and combines with immune checkpoint inhibitors to enhance strong and long term anti-tumor immunity
Abstract number: 2612
Presenting author: Minu Srivastava, Ph.D., Senior Scientist II
Session: Checkpoints 2: Small Molecule Inhibitors (Note: anti-TIGIT is a monoclonal antibody)
Location: Poster section 25; Poster board 1 Wednesday, April 5, 2017         8:00 AM - Noon
Title: Prevalence of GITR expression and pharmacodynamic (PD) biomarkers in syngeneic tumor models treated by a GITR agonist (GITRL-Fc)
Abstract number: 5621
Presenting author: Min Wang, Ph.D., Director, Translational Medicine
Session: Immune Checkpoints and Immunosurveillance
Location: Poster section 25; Poster board 23 About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics.  OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis.  Demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-DLL4/VEGF bispecific (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), anti-RSPO3 (OMP-131R10) and anti-TIGIT (OMP-313M32) are part of the company’s strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK).  OncoMed is independently developing brontictuzumab (anti-Notch1, OMP-52M51) and GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research efforts.  For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
Contact:
Michelle Corral
Senior Director, Investor Relations and Corporate Communications
OncoMed Pharmaceuticals
[email protected]
(650) 995-8373

Read more...

Ratios

vs
industry
vs
history
PS Ratio 5.05
OMED's PS Ratio is ranked higher than
53% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. OMED: 5.05 )
Ranked among companies with meaningful PS Ratio only.
OMED' s PS Ratio Range Over the Past 10 Years
Min: 1.03  Med: 13.06 Max: 26.12
Current: 5.05
1.03
26.12
EV-to-EBIT 0.19
OMED's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. OMED: 0.19 )
Ranked among companies with meaningful EV-to-EBIT only.
OMED' s EV-to-EBIT Range Over the Past 10 Years
Min: -32.7  Med: -7.1 Max: 0.3
Current: 0.19
-32.7
0.3
EV-to-EBITDA 0.19
OMED's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. OMED: 0.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
OMED' s EV-to-EBITDA Range Over the Past 10 Years
Min: -34.8  Med: -7.4 Max: 0.3
Current: 0.19
-34.8
0.3
Current Ratio 3.27
OMED's Current Ratio is ranked lower than
56% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. OMED: 3.27 )
Ranked among companies with meaningful Current Ratio only.
OMED' s Current Ratio Range Over the Past 10 Years
Min: 1.89  Med: 4.55 Max: 6.43
Current: 3.27
1.89
6.43
Quick Ratio 3.27
OMED's Quick Ratio is ranked lower than
54% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. OMED: 3.27 )
Ranked among companies with meaningful Quick Ratio only.
OMED' s Quick Ratio Range Over the Past 10 Years
Min: 1.89  Med: 4.55 Max: 6.43
Current: 3.27
1.89
6.43
Days Sales Outstanding 24.10
OMED's Days Sales Outstanding is ranked higher than
74% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. OMED: 24.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMED' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.22  Med: 59.49 Max: 996.38
Current: 24.1
0.22
996.38

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.10
OMED's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. OMED: -8.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OMED' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -212.7  Med: -107.4 Max: 0
Current: -8.1
-212.7
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.39
OMED's Price-to-Median-PS-Value is ranked higher than
54% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. OMED: 0.39 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OMED' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 1.05 Max: 2
Current: 0.39
0.09
2
Earnings Yield (Greenblatt) % 526.32
OMED's Earnings Yield (Greenblatt) % is ranked lower than
94% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. OMED: 526.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OMED' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 368.2  Med: 445.55 Max: 980.4
Current: 526.32
368.2
980.4

More Statistics

Revenue (TTM) (Mil) $25.02
EPS (TTM) $ -2.86
Beta2.74
Short Percentage of Float7.44%
52-Week Range $3.25 - 15.35
Shares Outstanding (Mil)37.62

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 24 49 25
EPS ($) -1.43 -0.08 -0.39
EPS without NRI ($) -1.43 -0.08 -0.39
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OMED

Headlines

Articles On GuruFocus.com
OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results May 08 2017 
OncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial May 04 2017 
OncoMed Pharmaceuticals to Report First Quarter Financial Results on May 8th, 2017 May 03 2017 
OncoMed Announces Workforce Reduction Apr 24 2017 
9 Stocks Primecap Management Continues to Buy Apr 20 2017 
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints Apr 17 2017 
OncoMed Pharmaceuticals Announces Bayer Terminates its Option to License Vantictumab or Ipafricept Apr 10 2017 
OncoMed’s Phase 2 Demcizumab Pancreatic Cancer Trial Misses Primary Endpoint Apr 10 2017 
OncoMed Highlights New Data Presented at the American Association for Cancer Research Annual Meeting Apr 05 2017 
OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Rese Apr 03 2017 

More From Other Websites
Newman Ferrara LLP Announces Corporate Governance Investigation of OncoMed Pharmaceuticals Inc. May 15 2017
Edited Transcript of OMED earnings conference call or presentation 8-May-17 12:30pm GMT May 12 2017
Human Antibody Discovery: Of Mice And Phage May 11 2017
Strike three: Peninsula biotech swings, misses on third cancer drug trial in past month May 09 2017
OncoMed Pharma stock drops 17% after clinical trial miss; Q1 revenue miss May 08 2017
Investor Network: OncoMed Pharmaceuticals, Inc. to Host Earnings Call May 08 2017
OncoMed reports 1Q loss May 08 2017
OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results May 08 2017
OncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial May 04 2017
OncoMed Pharmaceuticals to Report First Quarter Financial Results on May 8th, 2017 May 03 2017
[$$] Four Small Biotechs See Bullish April Stock Buys May 03 2017
Bay Area biotech slashes half of staff after drug partnerships falter Apr 24 2017
OncoMed to lay off half of its staff Apr 24 2017
OncoMed Announces Workforce Reduction Apr 24 2017
Here's Why OncoMed Pharmaceuticals (OMED) Stock Fell Today Apr 18 2017
OncoMed is having a no good, very bad week Apr 18 2017
OncoMed's lung cancer drug fails mid-stage study, shares tumble Apr 17 2017
Biotech Movers: OncoMed, Incyte, Omeros Apr 17 2017
OncoMed stock drops 25% after lung cancer drug misses in mid-stage clinical trial Apr 17 2017
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints Apr 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)